Related Experiment Video

Updated: Oct 13, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and

P Høgh1, A Oturai, K Schreiber

  • 1Department of Neurology, The Neuroscience Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|August 30, 2000
PubMed

Insights

The APOE-epsilon 4/epsilon 4 genotype is linked to a higher risk of developing Multiple Sclerosis (MS). MS patients with this genotype also show a faster disease progression rate.

Area of Science:

  • Genetics
  • Neurology
  • Epidemiology

Background:

  • The apolipoprotein E (APOE) gene is implicated in various neurological conditions.
  • Understanding the role of APOE genotype in Multiple Sclerosis (MS) susceptibility and progression is crucial.

Purpose of the Study:

  • To investigate the association between APOE genotype and Multiple Sclerosis (MS) risk.
  • To examine the relationship between APOE genotype and the rate of disease progression in MS patients.

Main Methods:

  • A cohort of 240 MS patients was studied over three years.
  • APOE genotyping was performed using PCR techniques on saliva and/or blood samples.
  • Progression rate was measured using the Expanded Disability Status Scale (EDSS) divided by disease duration.

Main Results:

  • APOE-epsilon 4/epsilon 4 homozygotes were found at a significantly higher frequency in the MS group compared to controls (odds ratio: 2.3, P<0.05).
  • No significant differences in genotype distribution were observed for other APOE genotypes.
  • MS patients with APOE-epsilon 4/epsilon 4 genotype exhibited a significantly faster rate of disease progression (P<0.05).

Conclusions:

  • The APOE-epsilon 4/epsilon 4 genotype may confer an increased risk of developing Multiple Sclerosis.
  • Individuals with the APOE-epsilon 4/epsilon 4 allele might experience a more rapid disease progression in MS.

More Related Videos

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...